Core Viewpoint - He Yuan Bio has successfully completed the listing of its drug Aofumin® (recombinant human albumin injection) in the procurement catalog across various provinces in China, and sales have begun nationwide [1] Group 1 - The company has confirmed that Aofumin® is now available for sale in all provinces following the completion of the procurement catalog listing [1] - He Yuan Bio has scheduled the disclosure of its 2025 annual report for April 28, 2026, indicating a commitment to transparency regarding its sales performance [1]